Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass.

OBJECTIVE To develop a new scoring system based on menopausal status, ultrasound (US) findings, serum cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) to predict ovarian cancer (OC) in women presenting with a pelvic or adnexal mass. METHODS Consecutive female patients aged over 18years with pelvic or adnexal masses investigated preoperatively by pelvic US, serum CA125 and HE4 who underwent elective surgery were enrolled. The "Rajavithi-Ovarian Cancer Predictive Score (R-OPS)" was developed using data from 2012 and validated using data from 2013 to 2014. The diagnosis of OC was based on pathological findings. Data were analyzed by logistic regression and area under the receiver operating characteristic curve (ROC-AUC). RESULTS Based on a development set of 260 women including 74 with OC, menopausal status (M), serum CA125 and HE4, and US findings of solid lesions (U) were identified as significant predictors of OC. R-OPS=M×U×(CA125×HE4)(1/2) revealed good calibration (goodness-of-fit test, p=0.972) and discrimination (ROC-AUC=92.8%). Performance validation in 266 women, 82 with OC, showed good discrimination with ROC-AUC of 94.9%. Performance in the validation sample with a cutoff value of R-OPS>330 revealed sensitivity, specificity, and positive and negative predictive values of 93.9%, 79.9%, 67.5%, and 96.7%, respectively. CONCLUSIONS The new R-OPS scoring system showed good discrimination between non-cancerous lesions and OC. However, a prospective study in a different setting is required to confirm these preliminary data.

[1]  B. van Calster,et al.  Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. , 2012, European journal of cancer.

[2]  Hui Lin,et al.  Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. , 2005, Fertility and sterility.

[3]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[4]  T. Aw,et al.  Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings , 2015, Journal of gynecologic oncology.

[5]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.

[6]  Y. Kunpalin,et al.  Proportion of ovarian cancers in overall ovarian masses in Thailand. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[7]  Steven J Skates,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[8]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[9]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[10]  Robert C. Bast,et al.  Ovarian cancer: screening, treatment, and followup. , 1995, NIH consensus statement.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[13]  I. Christensen,et al.  Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. , 2012, Gynecologic oncology.

[14]  J. Pailoor,et al.  Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[15]  I. Jacobs,et al.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1990 .

[16]  S. Huber,et al.  Value of ultrasound and magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. , 2002, Anticancer research.

[17]  Sabine Van Huffel,et al.  Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group , 2010, BMJ : British Medical Journal.

[18]  M. Panteghini,et al.  Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review , 2013, Journal of Clinical Pathology.

[19]  N. Smorgick,et al.  Assessment of adnexal masses using ultrasound: a practical review , 2014, International journal of women's health.

[20]  I. Timor-Tritsch,et al.  Transvaginal Sonographic Characterization of Ovarian Disease: Evaluation of a New Scoring System to Predict Ovarian Malignancy , 1991, Obstetrics and gynecology.

[21]  Steven J Skates,et al.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. , 2010, American journal of obstetrics and gynecology.

[22]  Jacobus Pfisterer,et al.  Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. , 2009, Gynecologic oncology.

[23]  K. Chao,et al.  Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. , 2014, Gynecologic oncology.

[24]  Jeong-Won Lee,et al.  Histologic distribution of borderline ovarian tumors worldwide: a systematic review , 2013, Journal of gynecologic oncology.